Search contract descriptions, companies and agencies.
ON BEHALF OF NIAID-DCR, FACILITATE THE CONDUCT OF TWO, RANDOMIZED TRIALS AS DETAILED BELOW IN I AND II:
I. A RANDOMIZED BLINDED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF INVESTIGATIONAL THERAPEUTICS FOR THE TREATMENT OF COVID-19 (2,000 SUBJECTS
Total Committed
$938M
Product or Service Description
Operation of Government Owned Contractor Operated R&D Facilities
Contracting Agency
Effective Date
Aug. 31, 2020
Funding Department
NIH NCI
Type
Cost plus fixed fee
Solicitation Procedure
Negotiated proposal/quote
Extent Competed
Full and open competition
Recent Contract Actions 
Contracts can have multiple “contract actions”: This is how agencies spend money for a specific purpose, adjust the amount committed or change the contract in a way that doesn’t affect the amount. That last scenario is usually indicated by a $0 action. If there is a contract action for a negative amount, it generally means the contract was adjusted or canceled.
| Vendor | Description | Signed | Reason for Change | Amount Committed |
|---|---|---|---|---|
| LEIDOS BIOMEDICAL RESEARCH, INC. | THE COVID 19 SERVICES CATALYZE TRANSLATIONAL RESEARCH FINDINGS INTO PUBLIC HEALTH CHANGES TO ADDRESS THE NOVEL CORONAVIRUS PANDEMIC THROUGH IMPLEMENTATION OF STANDARDIZED SEROLOGY TESTING FOR ITS INTENDED USES IN CANCER PATIENTS AND OTHERS. | Aug. 17, 2021 | Other Administrative Action | $24,886,601 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | NIAID VRC | July 15, 2021 | Other Administrative Action | $500,000 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | DCR IS REQUESTING THE SERVICES OF LEIDOS BIOMEDICAL RESEARCH, INC. TO INITIATE MANAGEMENT, OVERSIGHT, EXECUTION, CLOSEOUT AND PUBLICATION OF FINDINGS OF A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT AND PEDIATRIC PATIENTS WITH UNKNOWN FEBRILE ILLNESS FR | June 17, 2021 | Exercise An Option | $8,758,455 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | NCI OPERATIONAL TASK ORDER | June 2, 2021 | Other Administrative Action | $2,626,906 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | NIAID DIR | May 20, 2021 | Funding Only Action | $1,100,000 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | NIAID DCR OPERATIONAL TASK ORDER COVID FUNDING IN THE AMOUNT OF $3,706,224 FOR COVID RELATED EFFORTS ON THIS TASK ORDER | Feb. 25, 2021 | Other Administrative Action | $0 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | CENTER FOR SEROLOGICAL SCIENCES NETWORK (SERONET) | Feb. 10, 2021 | $86,551,385 | |
| LEIDOS BIOMEDICAL RESEARCH, INC. | COVID ACTIV3 TASK ORDER SUPPORTS NIAID'S GOAL TO BETTER UNDERSTAND THE CORONAVIRUS WITH AN INITIAL FOCUS ON ACTIV3. THIS TASK ORDER WILL INITIATE THE MANAGEMENT , OVERSIGHT , AND CONDUCT OF THE NIAID DCR CLINICAL TRIAL TITLED A MULTICENTER, ADA | Jan. 25, 2021 | Other Administrative Action | $0 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | NIAID COVID-19 ACTIV3 | Jan. 22, 2021 | Other Administrative Action | -$7,368,816 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | NCI FEDERALLY FUNDED RESEARCH AND DEVELOPMENT CENTER (FFRDC) CONTRACT | Jan. 21, 2021 | Other Administrative Action | $1,283,576 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | INITIATE THE MANAGEMENT, OVERSIGHT, AND CONDUCT OF THE NIAID DMID CLINICAL TRIAL TITLED "A MULTICENTER, ADAPTIVE, RANDOMIZED BLINDED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF INVESTIGATIONAL THERAPEUTICS FOR THE TREATMENT OF COVID-19". | Jan. 15, 2021 | Funding Only Action | $25,075,500 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | NIAID DMID BIG EFFECT TRIAL (BET) - INITIATE THE MANAGEMENT , OVERSIGHT , AND CONDUCT OF THE NIAID DMID CLINICAL TRIAL TITLED A MULTICENTER PLATFORM EVALUATING PUTATIVE THERAPEUTICS FOR THE TREATMENT OF COVID-19 IN HOSPITALIZED ADULTS (SHORT TITLE, | Jan. 15, 2021 | Other Administrative Action | $0 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | NIAID DCR OPERATIONAL TASK ORDER COVID FUNDING IN THE AMOUNT OF $3,706,224 FOR COVID RELATED EFFORTS ON THIS TASK ORDER | Jan. 13, 2021 | Other Administrative Action | $0 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | COVID ACTIV3 TASK ORDER SUPPORTS NIAID'S GOAL TO BETTER UNDERSTAND THE CORONAVIRUS WITH AN INITIAL FOCUS ON ACTIV3. THIS TASK ORDER WILL INITIATE THE MANAGEMENT , OVERSIGHT , AND CONDUCT OF THE NIAID DCR CLINICAL TRIAL TITLED A MULTICENTER, ADA | Nov. 23, 2020 | Other Administrative Action | $0 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | ON BEHALF OF NIAID-DCR, FACILITATE THE CONDUCT OF TWO, RANDOMIZED TRIALS AS DETAILED BELOW IN I AND II: I. A RANDOMIZED BLINDED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF INVESTIGATIONAL THERAPEUTICS FOR THE TREATMENT OF COVID-19 (2,000 SUBJECTS | Nov. 20, 2020 | Other Administrative Action | $0 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | NCI OPERATIONAL TASK ORDER | Nov. 12, 2020 | Other Administrative Action | $400,000 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | PRE-CLINICAL ASSESSMENT OF MONOCLONAL ANTIBODIES AND OTHER PROMISING VACCINES/AGENTS | Nov. 6, 2020 | Supplemental Agreement For Work Within Scope | $0 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | ON BEHALF OF NIAID-DCR, FACILITATE THE CONDUCT OF TWO, RANDOMIZED TRIALS AS DETAILED BELOW IN I AND II: I. A RANDOMIZED BLINDED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF INVESTIGATIONAL THERAPEUTICS FOR THE TREATMENT OF COVID-19 (2,000 SUBJECTS | Oct. 27, 2020 | Other Administrative Action | $0 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | NIAID DCR OPERATIONAL COVID RELATED EFFORTS | Oct. 27, 2020 | Other Administrative Action | $0 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | ON BEHALF OF DCR FACILITATE THE CONDUCT OF AN OBSERVATIONAL STUDY TO CHARACTERIZE PATIENTS WITH COVID-19 INFECTION (10,000 SUBJECTS). | Oct. 27, 2020 | Other Administrative Action | $0 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | NIAID COVID-19 ACTIV3 | Oct. 22, 2020 | Supplemental Agreement For Work Within Scope | $26,150,457 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | NCI OPERATIONAL TASK ORDER COVID-19: INITIATE DCEG COVID-19 CASE STUDY: YT 20-144. PID # 600.129.20.01.018.001.0005 COVID-19: INITIATE DCEG COVID-19 CASE STUDY FOR CGR USE UNDER YT 20-144. PID # 600.129.20.01.038.001.0281 | Oct. 13, 2020 | Other Administrative Action | $0 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | NCI OPERATIONAL TASK ORDER | Sept. 27, 2020 | Funding Only Action | $207,226,867 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | COVID ACTIV3 TASK ORDER SUPPORTS NIAID'S GOAL TO BETTER UNDERSTAND THE CORONAVIRUS WITH AN INITIAL FOCUS ON ACTIV3. THIS TASK ORDER WILL INITIATE THE MANAGEMENT , OVERSIGHT , AND CONDUCT OF THE NIAID DCR CLINICAL TRIAL TITLED A MULTICENTER, ADA | Sept. 1, 2020 | Other Administrative Action | $0 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | NIAID COVID-19 ACTIV3 | Sept. 1, 2020 | $198,740,313 | |
| LEIDOS BIOMEDICAL RESEARCH, INC. | NIAID DCR OPERATIONAL TASK ORDER COVID FUNDING IN THE AMOUNT OF $3,706,224 FOR COVID RELATED EFFORTS ON THIS TASK ORDER | Aug. 28, 2020 | $68,909,533 | |
| LEIDOS BIOMEDICAL RESEARCH, INC. | NIAID DIR | Aug. 25, 2020 | $6,882,557 | |
| LEIDOS BIOMEDICAL RESEARCH, INC. | NCI OPERATIONAL TASK ORDER COVID-19: INITIATE DCEG COVID-19 CASE STUDY: YT 20-144. PID # 600.129.20.01.018.001.0005 COVID-19: INITIATE DCEG COVID-19 CASE STUDY FOR CGR USE UNDER YT 20-144. PID # 600.129.20.01.038.001.0281 | Aug. 21, 2020 | Funding Only Action | $2,150,259 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | NCI OPERATIONAL TASK ORDER COVID-19: INITIATE DCEG COVID-19 CASE STUDY: YT 20-144. PID # 600.129.20.01.018.001.0005 COVID-19: INITIATE DCEG COVID-19 CASE STUDY FOR CGR USE UNDER YT 20-144. PID # 600.129.20.01.038.001.0281 | Aug. 18, 2020 | Other Administrative Action | $10,574,155 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | NCI OPERATIONAL TASK ORDER COVID-19: INITIATE DCEG COVID-19 CASE STUDY: YT 20-144. PID # 600.129.20.01.018.001.0005 COVID-19: INITIATE DCEG COVID-19 CASE STUDY FOR CGR USE UNDER YT 20-144. PID # 600.129.20.01.038.001.0281 | Aug. 14, 2020 | Funding Only Action | $4,550,785 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | NIAID DMID BIG EFFECT TRIAL (BET) - INITIATE THE MANAGEMENT , OVERSIGHT , AND CONDUCT OF THE NIAID DMID CLINICAL TRIAL TITLED A MULTICENTER PLATFORM EVALUATING PUTATIVE THERAPEUTICS FOR THE TREATMENT OF COVID-19 IN HOSPITALIZED ADULTS (SHORT TITLE, | Aug. 4, 2020 | Definitize Letter Contract | $14,320,095 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | ON BEHALF OF NIAID-DCR, FACILITATE THE CONDUCT OF TWO, RANDOMIZED TRIALS AS DETAILED BELOW IN I AND II: I. A RANDOMIZED BLINDED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF INVESTIGATIONAL THERAPEUTICS FOR THE TREATMENT OF COVID-19 (2,000 SUBJECTS | July 30, 2020 | Definitize Letter Contract | $33,788,063 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | NCI OPERATIONAL TASK ORDER COVID-19: INITIATE DCEG COVID-19 CASE STUDY: YT 20-144. PID # 600.129.20.01.018.001.0005 COVID-19: INITIATE DCEG COVID-19 CASE STUDY FOR CGR USE UNDER YT 20-144. PID # 600.129.20.01.038.001.0281 | July 27, 2020 | Other Administrative Action | $0 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | NCI OPERATIONAL TASK ORDER COVID-19: INITIATE DCEG COVID-19 CASE STUDY: YT 20-144. PID # 600.129.20.01.018.001.0005 COVID-19: INITIATE DCEG COVID-19 CASE STUDY FOR CGR USE UNDER YT 20-144. PID # 600.129.20.01.038.001.0281 | July 17, 2020 | Funding Only Action | $22,416,036 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | COVID ACTIV3 TASK ORDER SUPPORTS NIAID'S GOAL TO BETTER UNDERSTAND THE CORONAVIRUS WITH AN INITIAL FOCUS ON ACTIV3. THIS TASK ORDER WILL INITIATE THE MANAGEMENT , OVERSIGHT , AND CONDUCT OF THE NIAID DCR CLINICAL TRIAL TITLED A MULTICENTER, ADA | July 8, 2020 | Other Administrative Action | $0 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | PROVIDE THE FULL RANGE OF SERVICES REQUIRED TO SUPPORT DCR IN ITS PROVISION OF SUPPORT SERVICES, OVERSIGHT, AND MANAGEMENT OF INTRAMURAL CLINICAL RESEARCH, PROGRAM PLANNING AND MANAGEMENT, REGULATORY MONITORING AND COMPLIANCE, STATISTICAL CONSULTATIO | July 8, 2020 | Funding Only Action | $5,070,370 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | INITIATE THE MANAGEMENT, OVERSIGHT, AND CONDUCT OF THE NIAID DMID CLINICAL TRIAL TITLED "A MULTICENTER, ADAPTIVE, RANDOMIZED BLINDED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF INVESTIGATIONAL THERAPEUTICS FOR THE TREATMENT OF COVID-19". | June 30, 2020 | Definitize Letter Contract | $23,414,109 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | COVID ACTIV3 TASK ORDER SUPPORTS NIAID'S GOAL TO BETTER UNDERSTAND THE CORONAVIRUS WITH AN INITIAL FOCUS ON ACTIV3. THIS TASK ORDER WILL INITIATE THE MANAGEMENT , OVERSIGHT , AND CONDUCT OF THE NIAID DCR CLINICAL TRIAL TITLED A MULTICENTER, ADA | June 30, 2020 | $50,000,000 | |
| LEIDOS BIOMEDICAL RESEARCH, INC. | NCI OPERATIONAL TASK ORDER COVID-19: INITIATE DCEG COVID-19 CASE STUDY: YT 20-144. PID # 600.129.20.01.018.001.0005 COVID-19: INITIATE DCEG COVID-19 CASE STUDY FOR CGR USE UNDER YT 20-144. PID # 600.129.20.01.038.001.0281 | June 19, 2020 | Funding Only Action | $46,000,000 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | ON BEHALF OF DCR FACILITATE THE CONDUCT OF AN OBSERVATIONAL STUDY TO CHARACTERIZE PATIENTS WITH COVID-19 INFECTION (10,000 SUBJECTS). | June 10, 2020 | Supplemental Agreement For Work Within Scope | $7,568,588 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | PROVIDE THE FULL RANGE OF SERVICES REQUIRED TO SUPPORT DCR IN ITS PROVISION OF SUPPORT SERVICES, OVERSIGHT, AND MANAGEMENT OF INTRAMURAL CLINICAL RESEARCH, PROGRAM PLANNING AND MANAGEMENT, REGULATORY MONITORING AND COMPLIANCE, STATISTICAL CONSULTATIO | June 8, 2020 | Other Administrative Action | $0 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | NCI OPERATIONAL TASK ORDER COVID-19: INITIATE DCEG COVID-19 CASE STUDY: YT 20-144. PID # 600.129.20.01.018.001.0005 COVID-19: INITIATE DCEG COVID-19 CASE STUDY FOR CGR USE UNDER YT 20-144. PID # 600.129.20.01.038.001.0281 | June 4, 2020 | Other Administrative Action | -$393,000 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | PROVIDE THE FULL RANGE OF SERVICES REQUIRED TO SUPPORT DCR IN ITS PROVISION OF SUPPORT SERVICES, OVERSIGHT, AND MANAGEMENT OF INTRAMURAL CLINICAL RESEARCH, PROGRAM PLANNING AND MANAGEMENT, REGULATORY MONITORING AND COMPLIANCE, STATISTICAL CONSULTATIO | May 27, 2020 | Other Administrative Action | $0 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | INITIATE THE MANAGEMENT, OVERSIGHT, AND CONDUCT OF THE NIAID DMID CLINICAL TRIAL TITLED "A MULTICENTER, ADAPTIVE, RANDOMIZED BLINDED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF INVESTIGATIONAL THERAPEUTICS FOR THE TREATMENT OF COVID-19". | May 4, 2020 | Supplemental Agreement For Work Within Scope | $10,104,139 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | NCI OPERATIONAL TASK ORDER COVID-19: INITIATE DCEG COVID-19 CASE STUDY: YT 20-144. PID # 600.129.20.01.018.001.0005 COVID-19: INITIATE DCEG COVID-19 CASE STUDY FOR CGR USE UNDER YT 20-144. PID # 600.129.20.01.038.001.0281 | May 4, 2020 | Other Administrative Action | $0 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | NIAID DMID BIG EFFECT TRIAL (BET) - INITIATE THE MANAGEMENT , OVERSIGHT , AND CONDUCT OF THE NIAID DMID CLINICAL TRIAL TITLED A MULTICENTER PLATFORM EVALUATING PUTATIVE THERAPEUTICS FOR THE TREATMENT OF COVID-19 IN HOSPITALIZED ADULTS (SHORT TITLE, | May 1, 2020 | $11,490,292 | |
| LEIDOS BIOMEDICAL RESEARCH, INC. | PROVIDE THE FULL RANGE OF SERVICES REQUIRED TO SUPPORT DCR IN ITS PROVISION OF SUPPORT SERVICES, OVERSIGHT, AND MANAGEMENT OF INTRAMURAL CLINICAL RESEARCH, PROGRAM PLANNING AND MANAGEMENT, REGULATORY MONITORING AND COMPLIANCE, STATISTICAL CONSULTATIO | April 10, 2020 | Other Administrative Action | $0 |
| LEIDOS BIOMEDICAL RESEARCH, INC. | ON BEHALF OF DCR FACILITATE THE CONDUCT OF AN OBSERVATIONAL STUDY TO CHARACTERIZE PATIENTS WITH COVID-19 INFECTION (10,000 SUBJECTS). | April 1, 2020 | $4,926,752 | |
| LEIDOS BIOMEDICAL RESEARCH, INC. | INITIATE THE MANAGEMENT, OVERSIGHT, AND CONDUCT OF THE NIAID DMID CLINICAL TRIAL TITLED "A MULTICENTER, ADAPTIVE, RANDOMIZED BLINDED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF INVESTIGATIONAL THERAPEUTICS FOR THE TREATMENT OF COVID-19". | April 1, 2020 | $6,680,834 | |
| LEIDOS BIOMEDICAL RESEARCH, INC. | ON BEHALF OF NIAID-DCR, FACILITATE THE CONDUCT OF TWO, RANDOMIZED TRIALS AS DETAILED BELOW IN I AND II: I. A RANDOMIZED BLINDED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF INVESTIGATIONAL THERAPEUTICS FOR THE TREATMENT OF COVID-19 (2,000 SUBJECTS | April 1, 2020 | $33,571,749 |
About this data
This data comes from the Federal Procurement Data System, which includes all contracts worth $10,000 or more. We look at all contracts that are tagged with the procurement code for COVID-19 or otherwise started in 2020 and contain “COVID-19” in the description. Department of Defense contracting data is subject to a 90-day delay before it appears in the data.